Oppenheimer Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$437K Buy
+19,618
New +$469K 0.01% 895
2025
Q4
Sell
-21,843
Closed -$466K 1069
2025
Q3
$466K Sell
21,843
-11,856
-35% -$280K 0.01% 917
2025
Q2
$727K Sell
33,699
-2,165
-6% -$40.2K 0.01% 808
2025
Q1
$596K Buy
35,864
+3,535
+11% +$64.2K 0.01% 810
2024
Q4
$593K Sell
32,329
-5,100
-14% -$82.3K 0.01% 827
2024
Q3
$576K Buy
37,429
+7,872
+27% +$131K 0.01% 845
2024
Q2
$480K Buy
29,557
+2,842
+11% +$45.9K 0.01% 868
2024
Q1
$494K Sell
26,715
-7,367
-22% -$183K 0.01% 840
2023
Q4
$1.07M Sell
34,082
-2,111
-6% -$50.4K 0.01% 691
2023
Q3
$754K Buy
36,193
+10,789
+42% +$293K 0.01% 754
2023
Q2
$608K Buy
25,404
+8,502
+50% +$189K 0.01% 812
2023
Q1
$318K Buy
16,902
+3,378
+25% +$64.3K ﹤0.01% 953
2022
Q4
$215K Sell
13,524
-211
-2% -$3.3K ﹤0.01% 1055
2022
Q3
$225K Sell
13,735
-862
-6% -$14K ﹤0.01% 1022
2022
Q2
$206K Sell
14,597
-4,240
-23% -$79.1K ﹤0.01% 1074
2022
Q1
$456K Buy
18,837
+1,478
+9% +$35.8K 0.01% 936
2021
Q4
$405K Sell
17,359
-4,779
-22% -$96.1K 0.01% 1015
2021
Q3
$368K Sell
22,138
-6,559
-23% -$126K 0.01% 1004
2021
Q2
$700K Sell
28,697
-84
-0.3% -$1.9K 0.01% 857
2021
Q1
$743K Buy
28,781
+3,999
+16% +$176K 0.01% 814
2020
Q4
$1.32M Buy
24,782
+3,631
+17% +$180K 0.02% 598
2020
Q3
$872K Buy
21,151
+9,175
+77% +$396K 0.02% 663
2020
Q2
$580K Buy
11,976
+4,195
+54% +$201K 0.01% 757
2020
Q1
$329K Buy
7,781
+1,746
+29% +$71.9K 0.01% 843
2019
Q4
$258K Buy
6,035
+762
+14% +$33.1K 0.01% 992
2019
Q3
$190K Buy
5,273
+1,155
+28% +$35K ﹤0.01% 1044
2019
Q2
$110K Sell
4,118
-1,811
-31% -$46.3K ﹤0.01% 1201
2019
Q1
$159K Buy
5,929
+17
+0.3% +$397 ﹤0.01% 1090
2018
Q4
$96K Buy
+5,912
New +$115K ﹤0.01% 1197
2017
Q4
Sell
-842
Closed -$32K 1100
2017
Q3
$32K Sell
842
-4,291
-84% -$140K ﹤0.01% 1445
2017
Q2
$143K Buy
5,133
+468
+10% +$13.9K ﹤0.01% 1109
2017
Q1
$161K Buy
+4,665
New +$165K ﹤0.01% 1085

Other funds holding ACAD